Literature DB >> 1721105

Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida infections in normal and immunosuppressed mice.

A Polak-Wyss1.   

Abstract

Prophylactic treatment with human granulocyte colony stimulating factor (hG-CSF) affords significant protection against systemic infections caused by C. albicans in cyclophosphamide-treated but not in cortisone-treated mice. Localized candidosis in neutropenic mice does not respond to hG-CSF. Our data show that granulocytes play an important role in the immune defence against deep mycoses, but not against local infections. From our data it is reasonable to assume that prophylactic treatment with hG-CSF may augment the resistance of immunosuppressed patients to deep Candida infection, but it would be of little help against oral candidosis of HIV patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721105     DOI: 10.1111/j.1439-0507.1991.tb00630.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  10 in total

Review 1.  Key issues concerning fungistatic versus fungicidal drugs.

Authors:  J R Graybill; D S Burgess; T C Hardin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 2.  Hematopoietic growth factors in cancer patients with invasive fungal infections.

Authors:  F Offner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

Review 3.  Antifungal agents in the 1990s. Current status and future developments.

Authors:  C A Kauffman; P L Carver
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection.

Authors:  T Kuhara; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

5.  Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis.

Authors:  Andriani C Patera; Frederick Menzel; Craig Jackson; Joan K Brieland; Judy Halpern; Roberta Hare; Anthony Cacciapuoti; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 6.  Modulating host immune responses to fight invasive fungal infections.

Authors:  James E Scriven; Mark W Tenforde; Stuart M Levitz; Joseph N Jarvis
Journal:  Curr Opin Microbiol       Date:  2017-11-15       Impact factor: 7.934

Review 7.  Production and function of cytokines in natural and acquired immunity to Candida albicans infection.

Authors:  R B Ashman; J M Papadimitriou
Journal:  Microbiol Rev       Date:  1995-12

8.  Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis.

Authors:  J R Graybill; R Bocanegra; M Luther
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-08       Impact factor: 3.267

9.  Candida albicans induces mucosal bacterial dysbiosis that promotes invasive infection.

Authors:  Martinna Bertolini; Amit Ranjan; Angela Thompson; Patricia I Diaz; Takanori Sobue; Kendra Maas; Anna Dongari-Bagtzoglou
Journal:  PLoS Pathog       Date:  2019-04-22       Impact factor: 7.464

10.  The Effects of Granulocyte Colony-Stimulating Factor (G-CSF) in Pre-Clinical Models of Infection and Acute Inflammation.

Authors:  John C Marshall
Journal:  Sepsis (Boston)       Date:  1998
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.